Evidence based case report: Pyridoxine supplementation in children with pervasive developmental disorders

  • Sekarpramita Darmaputri University of lndonesia Medical School
  • Tjhin Wiguna University of lndonesia Medical School

Abstract

Pervasive developmental disorders (PDD)
is defined as a neurodevelopmental disorder,
c haract erized by social withdrawal,
communication deficits, and repetitive
behaviors. PDD include autistic disorder, Rett's
syndrome, childhood disintegrative disorder, Asperger' s
syndrome, and pervasive developmental disorder not
otherwise specified or atypical autism.1 Update of
epidemiological studies published between 1966 and
2006 show reports of estimated prevalence for autism
has varied between 3 .31 and 86 children per 10,000, 2
and predominantly occurs in males than females
(male:female ratio = 4: 1) .3
There is a hypothesis that behavioral problems
in children with pervasive developmental disorder
are highly associated with the neurotransmitter
imbalances. Therefore, psychotropic medications (eg.
atypical antipsychotics, selective serotonin reuptake
inhibitors, and psychostimulants), which work on
dopamine and serotonin receptors, are the FDAapproved
medications for PDD.4 On the other hands,
the use of novel, unconventional, and/or off- label
treatments associated with the n eurotransmitters
pathway for children with POD is increasing and
more common.

References

Currenti S. Understanding and determining the etiology of autism. Cell Mol Neurobiol. 2010;30:161-71.

Hughes J. Update on autism: A review of 1300 reports published in 2008. Epilepsy & Behavior. 2009;16:569-89.

Levy S, Mandell D, Schultz R. Autism. Lancet. 2009;374:1627-38.

Bonish V. Experiences with vitamin B6 with brain-damaged children with autistic syndrome. Proxis der Kinderpsychologie. 1968;309:445-7.

Adams J, Holloway C. Pilot Study of a Moderate Dose Multivitamin/ Mineral Supplement for Children with Autistic Spectrum Disorder. The Journal of Alternative and Complementary Medicine. 2004;10(6):1033-9.

Adams J, George F, Audhya T. Abnormally high plasma levels of vitamin B6 in children with autism not taking supplements compared to controls not taking supplements. J Altem Complement Med. 2006;12(1):59-63.

Pfeiffer S, Norton], Nelson L, Shott S. Efficacy ofVitamin B6 and Magnesium in the Treatment of Autism: A Methodology Review and Summary of Outcomes. J Autism Dev Disord. 1995;25:481-93.

Ames B, Elson-Schwab I, Silver E. High-dose vitamin therapy stimulates variant enzymes with decreased coenzymes binding affinity (increased Km): Relevance to genetic disease and polymorphisms. Am J Clin Nutr. 2002;75:616-58.

Murza K, Pavelko S, Malani M, Nye C. Vitamin B6-magnesium treatment for autism: the current status of the research. Magnesium Research. 2010;23(2):115-7.

Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. The Cochane Collaboration. 2005:1-19.

Rossignol D. Novel and emerging treatment for autism spectrum disorders: a systematic review. Annals of Clinical Psychiatry. 2009;21:213-36.

Findling R, Maxwell K, Scotese-Wojtila L, Husang J, Yamashita T, Wiznitzer M. High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord 1997;27:467-78.

Kuriyama S, Karniyama M, Watanabe M, Tamahashi S, Muraguchi I, Watanabe T, et al Pyridoxine treatment in a subgroup of children with pervasive developmental disorders. Developmental Medicine & Child Neurology. 2002;44:283-6.

Tolbert L, Haigler T, Waits M, Dennis T. Brief report: Lack ofresponse in an autistic population to a low dose clinical trial of pyridoxine plus magnesium. J Autism Dev Disord. 1993;23:193-9.

Buitelaar J, Willemsen-Swinkels S. Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy. Paediatr Drugs. 2000;2:67-81.

Martineau J, Barthelemy C, Garreau B, Lelord G. Vitamin B6, Magnesium, and Combined B6-Mg: Therapeutic Effects in Childhood Autism. Biol Psychiatry. 1985;20:467-78.

Schaumburg H, Kaplan], Winderbank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med. 1983;309:445-7.

University of Virginia: Health System. Peripheral Neuropathy and Vitamin B6. Virginia: University of Virginia; [29 April 2012); Available from: http://uvahealth.com/services/cancer-center/imagesand-docs/neuropathy.pdf.

Rimland B. An orthomolecular study of psychotic children. Orthomolecular psychiatry. 1974;3:371-7.

Dolske M, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid supplemental therapy for autism. Frog Neuropsychophatmacol & Biol Psychiatry. 1993;17:765-74.

Published
2014-06-30
How to Cite
1.
Darmaputri S, Wiguna T. Evidence based case report: Pyridoxine supplementation in children with pervasive developmental disorders. PI [Internet]. 30Jun.2014 [cited 29Mar.2024];54(3):186-2. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/520
Section
Articles
Received 2016-09-09
Accepted 2016-09-09
Published 2014-06-30